jj_sign_on_wall

J&J pledges to end global TB pandemic

pharmafile | September 25, 2018 | News story | Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis 

Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s most deadly infectious disease.

Through efforts to improve detection, broaden access to treatments, and accelerate R&D, the American pharma firm hope to save 1.8 million lives while preventing 12 million new TB infections, over the next ten years.

“TB is the world’s number one infectious killer, and TB and MDR-TB cause major devastation for people, communities and entire countries around the world,” Dr Paul Stoffels , Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, said in a statement. “The good news is TB is both preventable and treatable, and Johnson & Johnson is committed to doing everything we can to create a world free from TB. This new initiative will unleash the power of science and technology to forever change the trajectory of TB.”

While 10 million people fall ill with tuberculosis each year approximately 1.6 million die. However current treatments have particularly low cure rates and can equally lead to debilitating and even fatal side effects. The disease is also developing resistance to first line medicines as drug resistant TB now accounts for approximately one third of AMR related deaths.

As such, Jaak Peeters, Global Head, Johnson & Johnson Global Public Health, Janssen-Cilag GmbH, commented: “Our goal is to end the TB epidemic forever by finding and treating patients all over the world.”

Louis Goss

Related Content

FDA approves J&J’s Opsynvi for PAH treatment

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx …

J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …

Latest content